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ABSTRACT
Background and Aims Young adults with attention deﬁcit/hyperactivity disorder (ADHD) show higher substance use
disorder (SUD) prevalence relative to non-ADHD controls; few longitudinal studies have examined the course of substance
use with reference to conduct disorder (CD). We compared initiation and escalation of substance use at 15-month follow-
up in men screened positive or negative for ADHD (ADHD+ versus ADHD–), controlling for CD presence in early adoles-
cence. Design Participants were recruited during August 2010 and November 2011 from the census of all young
men who have to pass mandatory army conscription from three of six Swiss Army recruitment centres. A two-wave data
collectionwas performed via questionnaires at baseline and 15-month follow-up as a part of the longitudinal Cohort Study
on Substance Use Risk Factors. Setting Recruitment centres in Lausanne,Windisch andMels, responsible for 21 cantons
in German- and French-speaking areas of Switzerland. Participants Consecutive sample of 5103male Swiss Army con-
scripts who provided informed consent and responded to questionnaires at baseline and 15-month follow-up. Their mean
age was 20.0 (standard deviation=1.21) years at baseline.Measurements ADHD and CDwere assessed using the adult
ADHD Self-Report Scale and the MINI International Neuropsychiatric Interview Plus, respectively, at baseline, and sub-
stance use was measured via self-administered substance use questionnaires at baseline and follow-up.
Findings Compared with the ADHD– group, the ADHD+ group (n=215, 4.2%) showed heavier baseline substance
use and increased likelihood of alcohol (χ2=53.96; P<0.001), tobacco (χ2=21.73; P<0.001) and cannabis use disor-
ders (χ2=48.43; P<0.001). The extent of alcohol, tobacco and cannabis use in the two groups remained stable from
baseline to follow-up (no escalation). The ADHD+ group was more likely to initiate substance use compared with the
ADHD– group (higher initiation rates), particularly with amphetamines [odds ratio (OR)=3.81; 95% conﬁdence interval
(CI)=2.20–6.60; P<0.001] and non-medical use of ADHDmedication (OR=4.45; 95% CI=2.06–9.60; P<0.001). CD
was associated with initiation of substance use but did not mediate the associations between ADHD and substance use,
revealing that the impact of ADHD on substance use was independent of CD. Conclusions For men in their early 20s,
attention deﬁcit/hyperactivity disorder is a risk factor for continued heavier but not escalating use of alcohol, tobacco
and cannabis when already consuming these substances, compared with young men with no ADHD. It is also a risk factor
for initiating the use of cannabis, stimulants, hallucinogens and sedatives, independent of conduct disorder in early
adolescence.
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INTRODUCTION
Attention deﬁcit/hyperactivity disorder (ADHD), which in-
volves inattention, hyperactivity and impulsivity [1], is a
common childhood disorder with an estimated world-wide
prevalence rate of 3.4% in children and adolescents [2]. In
approximately half to two-thirds of cases, symptoms and
impairment associated with the disorder persist into adult-
hood [3,4]. Having a childhood history of ADHD and per-
sistent ADHD are both associated with higher prevalence
and a more severe and chronic course of substance use dis-
orders (SUDs) in adolescence and adulthood [4–8], indicat-
ing that ADHD contributes to an earlier SUD onset [9] and
a longer SUD duration [9,10].
Several longitudinal studies have examined the course
of SUD diagnoses such as substance abuse or dependence.
Two meta-analyses demonstrated that subjects with child-
hood ADHD were more likely to develop alcohol, nicotine,
cannabis, cocaine and other illicit drug abuse or depen-
dence in late adolescence or early adulthood [5,8].
Biederman et al. [11] also reported a more rapid progres-
sion from substance abuse to dependence among 140
ADHD male adolescents within 4 years when compared
to 120 normal control subjects. Recent studies continued
to conﬁrm that individuals with persistent ADHD are more
likely to develop SUD between late adolescence and early
adulthood compared to those without ADHD, suggesting
that once individuals with ADHD have developed SUD in
adolescence, SUD prevalence remains stable until early
adulthood [12–16]. Moreover, as long as individuals with
ADHD did not develop SUD prior to early adulthood, they
did not appear to be at a higher risk of doing so later in life
[15,17].
Although there are studies on SUD, little is known
about the course of substance use in early adulthood, par-
ticularly with respect to whether there is a change in sub-
stance use (e.g. escalation of cannabis use) and/or
initiation of substance use (e.g. starting cannabis use) in
those individuals with an ADHD. To our knowledge, only
two prospective studies have examined the escalation or
initiation of use of separate substances. Molina & Pelham
[18] observed an association between ADHD persistence
and higher rates of daily cigarette smoking, repetitive
drunkenness and alcohol-related problems in 142 adoles-
cents diagnosed with childhood ADHD compared to 100
controls. Individuals with persistent ADHD were three
times more likely to have used inhalants, hallucinogens
and cocaine and engaged in non-medical use of prescrip-
tion stimulants. Sibley et al. [19] showed that 113 individ-
uals who were diagnosed with ADHD in early childhood
and initiated cigarette and cannabis use in early adoles-
cence were four to ﬁve times more likely to progress to
heavy use of these substances by the age of 18years rela-
tive to 65 individuals without ADHD. These results provide
some evidence for the assumption that individuals with
ADHD show an initiation and/or escalation in the use of
certain substances between late adolescence and early
adulthood compared to those without ADHD.
In epidemiological and clinical samples, ADHD and
conduct disorder (CD) were found to occur together in
30–50% of cases, most probably as a result of shared ge-
netic and environmental inﬂuences between the two disor-
ders rather than an aetiologically distinct subtype or a
third, independent disorder [20]. However, few studies on
ADHD adjusted for CD. Evidence as to whether children
with ADHD and comorbid CD are at the highest risk of de-
veloping SUD is equivocal [21]. Two studies have shown a
mediatory effect of CD, in that ADHDwas no longer related
signiﬁcantly to SUD development if CD was controlled for.
Moreover, ADHD was associated signiﬁcantly with CD,
which was related signiﬁcantly to substance use outcomes
[19,22]. However, most studies still demonstrated signiﬁ-
cant effects of ADHD on substance use outcomes after con-
trolling for CD and showed additional signiﬁcant effects of
CD on substance use outcomes, independent of an ADHD
diagnosis [11,13,16,18,23,24]. These ﬁndings suggest
that ADHD and CD are likely to contribute independently
to a higher risk of SUD development, and in some cases
ADHDcould be a risk factor for CD development. Therefore,
it is important to control for CD, testing it as a mediator in
prospective studies examining associations between ADHD
and the course of substance use.
The aim of the present prospective study was to deter-
mine the initiation of substance use at 15-month follow-
up among baseline non-users and to examine the course
of substance use (escalation) at 15-month follow-up
among baseline users in a large sample of Swiss men in
their early 20s. Speciﬁcally, we expected increased frequen-
cies of initiation of use of alcohol, tobacco, cannabis and
other drugs, particularly of stimulants including all types
of amphetamines, ADHD medication and cocaine, in base-
line non-users screened positive for ADHD (ADHD+), rela-
tive to those screened negative for ADHD (ADHD–).
Among baseline users, we hypothesized that alcohol, to-
bacco and cannabis use escalation could be observed in
the ADHD+ group but not in the ADHD– group. Finally,
we expected that ADHD would be an independent predic-
tor of substance use initiation and escalation, particularly
for stimulants, even if CD was included as a mediator in
the relationship between ADHD and substance use out-
comes, and even if CD contributed to initiation and escala-
tion independently.
METHOD
Participants and procedures
The current study analysed data from the longitudinal Co-
hort Study on Substance Use Risk Factors (C-SURF) [25],
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which examined substance use patterns in young Swiss
men. Participants were recruited from three of
Switzerland’s six army recruitment centres (Lausanne,
Windisch and Mels). In Switzerland, army recruitment is
mandatory for men nearing 19years of age to determine
their eligibility for military or civil service. Due to manda-
tory conscription there are no preselection criteria, e.g. af-
ﬂuence or education as in college student samples. The
three recruitment centres cover 21 of 26 Swiss cantons,
andwe used them solely for participant recruitment. These
centreswere chosen for the following reasons: the centre in
Lausanne is responsible for all French-speaking Swiss men,
Windisch is the largest centre with the largest number of
German-speaking Swiss conscripts and Mels is responsible
for eastern Switzerland. Thus, men from the Italian-
speaking region and from Zurich were excluded from the
sample. In total, 15066 Swiss men attended the three
army recruitment centres within 1year (between August
2010 and November 2011 at the latest). This is a quasi-
census of all men called for conscription during this period
in these three centres. Exceptions were those who did not
show up after convocation and those who were severely
disabled. Principally, all men were eligible for study partic-
ipation, which was independent of their suitability for mil-
itary service. Therefore, not only did the sample include
recruits serving in the army but also civil servants and
those judged not being able for any service. Participants
were assured of strict conﬁdentiality, and they were
assessed outside themilitary environment. Therefore, those
who provided written informed consent received the base-
line questionnaire approximately 2weeks later at their
home addresses. Questionnaires could be completed via pa-
per and pencil or online. Baseline data were collected be-
tween August 2010 and March 2012, as data collection
lasted longer than enrolment during army conscription,
and the young men received the follow-up questionnaire
approximately 15months after the completion of the base-
line questionnaire.
Of the total sample (census), 1829men could not be in-
formed about the study during army recruitment proce-
dures because of organizational reasons, leaving 13237
potential participants. Of these, 7556 (50.1% of the eligible
population) provided written informed consent to partici-
pate in the C-SURF. Despite extensive efforts to encourage
all young men who provided informed consent for partici-
pation in the Army centres to complete the baseline ques-
tionnaire, only 5990 men (79.3%) did so at baseline, and
of these 5464 participated at follow-up (91.2%). Reasons
for silent refusal among consenters were that they lost in-
terest in the study or that they believed that signing the
consent form was mandatory, as it was asked during the
army recruitment procedures. Two published reports
showed that differences between respondents, non-
respondents and non-consenters were small [26,27] and
showed different substance use trends, i.e. non-con-
senters/non-respondents were more often users of some
substances, but less often users of other substances. Owing
to missing data for at least one of the analysed variables,
data for 361 men (ADHD+ group: 9; ADHD– group: 352)
were excluded from the analysis, leaving a total sample of
5103 young men. The study protocol (Protocol no.
15/07) was approved by the Lausanne University Medical
School Clinical Research Ethics Committee.
Measures
Assessment of socio-demographic characteristics and ADHD
All assessment instruments can be found on the C-SURF
website [25]. ADHD and socio-demographic characteris-
tics, i.e. age, marital status, highest educational level and
current employment, were assessed at baseline.
Current ADHD was assessed using the adult ADHD
Self-Report Scale (ASRS version 1.1), a short screening
scale developed by the World Health Organization for use
in general population screening [28]. The ASRS consists
of six questions concerning the frequency of recent ADHD
symptoms, based on the diagnostic criteria of the Diagnos-
tic and Statistical Manual of Mental Disorders, 5th edition
(DSM-5) [1]. In this study, each of the six questions asked
how often a symptom had occurred over the preceding
12months, with responses provided using a ﬁve-point
scale ranging from 0 (‘never’) to 4 (‘very often’). The total
score ranged from 0 to 24. As proposed by Kessler et al.
[29], a score of 14 was deﬁned as the cut-off point for
ADHD+ versus ADHD–. In a previous study that used this
cut-off point, 64.9% of clinician-deﬁned ADHD cases and
93.9% of clinician-deﬁned non-ADHD cases were classiﬁed
correctly in a sample of 218 participants [29].
CD in early adolescence was assessed retrospectively
using the self-report version of the Mini International Neu-
ropsychiatric Interview Plus, which measures six behav-
iours (e.g. destruction of property and frequent aggression
towards people and animals) exhibited before the age of
15 years [30], as part of the antisocial personality disorder
diagnostic criteria. In early adolescence, if two or more of
the dichotomous items (no=0; yes=1) receive a response
of ‘yes’, the individual is considered to have a CD.
Assessment of substance use
Substance use was measured at baseline and follow-up
with a recall period of 12months. Alcohol use was assessed
by asking participants about whether they had consumed
any type of alcohol in the preceding 12months, the num-
ber of days per week that involved alcohol consumption
and the number of standard drinks (i.e. 10–12g pure alco-
hol) they consumed on a usual drinking day. High-risk
binge drinking was deﬁned as the consumption of six or
ADHD and substance use 1869
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more standard drinks on one occasion at least monthly
[31]. Alcohol abuse and dependence were assessed via a
questionnaire [32] based on the diagnostic criteria of the
DSM-5 diagnostic criteria and included items adapted orig-
inally from the Semi-Structured Assessment for the Genet-
ics of Alcoholism [33,34].
For tobacco use, participantswere asked aboutwhether
they had smoked in the preceding 12months, the number
of days per week that involved smoking and the number of
cigarettes they smoked on a usual smoking day. Nicotine
dependence was assessed using the Fagerström Test for
Nicotine Dependence [35].
Regarding cannabis use, participants were asked about
whether they had used cannabis in the preceding
12months, the frequencyof cannabis used and the number
of hours spent under the inﬂuence of cannabis on days on
which they used it. Cannabis use disorder was determined
using the Cannabis Use Disorder Identiﬁcation Test [36].
The use of illicit drugs in the preceding 12months was
measured, including drugs such as amphetamines and
methamphetamines (known as speed), 3,4-methylenedioxy-
methamphetamine (known as MDMA/ecstasy), hallucino-
genic mushrooms, psilocybin, peyote and mescaline and
other hallucinogens such as lysergic acid diethylamide
(known as LSD), phencyclidine (known as PCP/angel dust),
2,5-dimethoxy-4-bromophenethylamine (known as 2C-B)
and 2,5-dimethoxy-4-iodophenethylamine (known as 2C-I);
heroin; and cocaine/crack/freebase.
Non-medical use of prescription drugs was determined
by asking participants whether they had taken ADHD
medication such as methylphenidate (e.g. Ritalin®) or am-
phetamine sulphate (e.g. Aderall®), or sedatives, such as
hypnotics or tranquillizers, without a prescription or for
any reason other than those for which the substance is pre-
scribed by a physician, in the preceding 12months.
Statistical analysis
χ2 and independent-sample t-tests were performed using
SPSS version 23 to compare socio-demographic character-
istics and substance use outcomes at baseline between the
ADHD+ and ADHD– groups. For t-tests of continuous vari-
ables, when the variable was positively skewed, the values
were square root-transformed to produce normality.
Random-effect multiple regression analyses were
performed in Stata intercooled 14 to account for random
centre clustering effects using the xtreg procedure for con-
tinuous outcomes on change between baseline and follow-
up (i.e. standard drinks, cigarette use per week and days of
cannabis use per year) among baseline users. Random-
effect logistic regression analyses were performed using
the Stata procedure xtlogit for dichotomous outcomes
(i.e. any use of alcohol, tobacco, cannabis or illicit drugs
and non-medical use of prescription drugs in the preceding
12months) on initiating substance use among baseline
non-users of the corresponding substance. All multiple
regression analyses controlled for socio-demographic char-
acteristics. Random-effect mediation analyses were per-
formed using the baseline measure of CD as a mediator.
Changes in the effects of substance use on ADHD without
CD were compared with the direct paths that included
CD as a mediator (c′; see Fig. 1). A change in the amount
and signiﬁcance of effects with and without the mediator
was considered to indicate mediation. Paths from ADHD
to CD (a) and from CD to substance use (b) were also
analysed (see Fig. 1). A mediation analysis was chosen be-
cause ADHD and CD most probably share genetic and en-
vironmental inﬂuences and ADHD precedes CD
chronologically [20]. We also tested the random-effect
moderation of ADHD by CD, as suggested by an anony-
mous referee on an earlier version of the present paper.
RESULTS
Socio-demographic characteristics and ADHD symptom
groups
Socio-demographic characteristics for the two groups have
been summarized in Table 1, using a dichotomous classiﬁca-
tion: ‘ADHD–’ (ASRS score 0–13 for 4888 men: 95.8%) and
‘ADHD+’ (ASRS score 14–24 for 215 men: 4.2%). Partici-
pants’ mean age at baseline was 20.0 [standard deviation
(SD)=1.21] years. ADHD+ and ADHD– were not statisti-
cally different with reference to socio-demographics, but
the ADHD+ group was signiﬁcantly more likely to have been
screened positive for CD compared with the ADHD– group.
Baseline substance use
Using the dichotomous classiﬁcation described above, par-
ticipants who screened positive for ADHD showed
Figure 1 Mediation analysis with attention deﬁcit/hyperactivity disorder (ADHD) as the predictor, substance use as the dependent variable and con-
duct disorder (CD) as the mediator. Paths a, b and c′ (for explanation see statistical analysis)
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signiﬁcantly higher baseline substance use rates compared
with those who were screened negative for ADHD (see
Table 2). Alcohol use outcomes in the 12months preced-
ing baseline assessment indicated that the quantity of alco-
hol consumed daily, number of drinking days and weekly
frequency of alcohol use were signiﬁcantly higher in the
ADHD+ group compared to those in the ADHD– group.
The prevalence of high-risk binge drinking and of alcohol
use disorder were also considerably higher in the ADHD+
group relative to those of the ADHD– group.
Compared to the ADHD– group, the ADHD+ group rel-
ative to those of the ADHD– group showed signiﬁcantly
higher smoking patterns on all measured variables, includ-
ing nicotine dependence prevalence, which was more than
two times higher.
There were signiﬁcant between-group differences in
cannabis use prevalence in the preceding 12months. The
annual frequency of cannabis use was non-signiﬁcant, but
the number of hours under the inﬂuence of cannabis per
use day in the ADHD+ group was signiﬁcantly higher than
that of the ADHD– group. The number of men whomet the
cannabis use disorder criteriawas almost three times higher
in the ADHD+ group than that in the ADHD– group.
Further, the presence of ADHD was associated signiﬁ-
cantly with amphetamine, ecstasy, hallucinogen and
cocaine use as well as of non-prescribed use of ADHDmed-
ication and sedatives. There were no signiﬁcant between-
group differences in heroin use prevalence.
Change in substance use from baseline to follow-up
There were no signiﬁcant effects of ADHD on changes in
nicotine and cannabis use from baseline to follow-up (see
Table 3), and signiﬁcant change in alcohol use became
non-signiﬁcant when controlling for CD (see Table 4).
However, the signiﬁcant group effects shown in Table 2 in-
dicate that overall numbers of standard drinks consumed
weekly, cigarettes smoked weekly and days of cannabis
use per year were signiﬁcantly higher in the ADHD+ group
compared to those of the ADHD– group.
There was a signiﬁcantly greater initiation of all illicit
substances (including non-medical use of ADHD medicine
and sedatives) in the ADHD+ group relative to those of the
ADHD– group; the prevalence rates for initiation of the licit
substances alcohol and tobacco did not differ signiﬁcantly
between groups.
When including CD as mediator, the effects of ADHD
remained unchanged except that changes in alcohol use
and initiation of ecstasy became non-signiﬁcant (see
Table 4). Thus, the effects of ADHD were mainly
Table 1 Baseline socio-demographic characteristics for the attention deﬁcit/hyperactivity disorder (ADHD)-negative and ADHD-positive
groups.
ADHD-negative
(ASRS< 14; n = 4888)
ADHD-positive
(ASRS ≥ 14; n = 215)
Mean/% (n) SD Mean/% (n) SD t/χ2 P
Age (years) 20.0 1.21 20.1 1.22 –1.36 0.178
Marital status 2.18 0.536
Married 0.6 (27) 0.5 (1)
In a relationship 4.4 (215) 2.4 (5)
Single 95.0 (4609) 97.2 (206)
Divorced 0.0 (1) 0.0 (0)
Education 6.01 0.111
Lower than high school 49.9 (2416) 47.2 (100)
High school 23.7 (1150) 19.3 (41)
High school + 2 years 24.9 (1206) 31.1 (66)
College 1.5 (74) 2.4 (5)
Employment 3.18 0.529
High school/college 74.9 (3621) 75.4 (159)
Employed (incl. unskilled work)
or self-employed
17.6 (852) 15.6 (33)
Unemployed 5.0 (243) 5.2 (11)
Welfare/disability pension 0.3 (13) 0.0 (0)
Other (sabbatical, internship, military
or civil service)
2.2 (108) 3.8 (8)
Conduct disorder in early adolescence 23.64 < 0.001
Yes 18.8 (913) 32.5 (69)
No 81.2 (3940) 67.5 (143)
ASRS = adult ADHD Self-Report Scale; n varies from 5048 to 5103 because of missing data. SD = standard deviation.
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independent of the effects of CD, which had signiﬁcant ef-
fects on all substance use variables with the exception of
changes in cigarette use and initiation of drinking alcohol
(see Table 4).
We tested additionally for an ADHD by CD modera-
tion. Moderation effects were largely non-signiﬁcant
(P>0.1), with two exceptions: for changes in alcohol
use the main effects of ADHD [b= –0.30; 95% conﬁ-
dence interval (CI) = –2.30, 1.71; P=0.770) and CD
(b= –0.72; 95% CI= –1.59, 0.15; P=0.103) were non-
signiﬁcant. Only the interaction effect of ADHD and CD
was signiﬁcant (b= –4.23; 95% CI= –7.82, –0.65;
P=0.021), showing a reduction in alcohol use between
baseline and follow-up in men with both ADHD and
CD. The second signiﬁcant moderation was found for
the initiation of amphetamine/methamphetamine use:
the negative interaction effect (b= –1.31; 95% CI= –
2.56, –0.07; P=0.039) together with the positive main
effects for ADHD (b=1.69; 95% CI=1.05, 2.34;
P<0.001) and CD (b=1.13; 95% CI=0.73, 1.52;
P<0.001) indicates a similarly higher incidence of
amphetamine/methamphetamine use among ADHD+-
only men compared with men being screened positively
for both ADHD and CD; that is, the incidence is similarly
high independent of the presence of CD. The incidence
was also higher for men with CD only but without
ADHD. The effects of the moderation analysis of ADHD
and CD for amphetamine/methamphetamine use are il-
lustrated in Fig. 2.
DISCUSSION
This longitudinal study compared substance use patterns
in 215 men who were screened positive for ADHD with
Table 2 Substance use in the attention deﬁcit/hyperactivity disorder (ADHD)-negative and ADHD-positive groups in the 12months
preceding baseline assessment.
ADHD-negative
(ASRS< 14; n = 4888)
ADHD-positive
(ASRS ≥ 14; n = 215)
Mean/% (n/N) SD Mean/% (n/N) SD t/χ2 P
Alcohol
Abstinence 7.6 (373/4888) 7.4 (16/215) 0.00 1.000
Drinking days per weeka 1.7 1.37 2.0 1.70 –2.70 0.008
Standard drinks per drinking daya 4.3 3.76 5.1 4.23 –2.72 0.007
Standard drinks per weeka,b 7.7 12.01 11.0 17.25 –3.23 0.001
High-risk binge drinking 45.1 (2198/4873) 54.2 (116/214) 6.48 0.011
Any alcohol use disorder 9.5 (466/4883) 25.4 (54/213) 53.96 <0.001
Tobacco
Smoking 45.2 (2207/4886) 57.7 (124/215) 12.48 <0.001
Smoking days per weeka 4.2 2.97 4.9 2.81 –2.59 0.011
Cigarettes per smoking daya 8.4 7.22 11.1 8.61 –3.22 0.002
Cigarettes per weeka,b 49.4 54.75 69.1 66.10 –3.46 0.001
Nicotine dependence 9.9 (483/4888) 20.0 (43/215) 21.73 <0.001
Cannabis
Cannabis use 29.3 (1432/4888) 49.3 (106/215) 38.20 <0.001
Days of cannabis use per yeara,b 89.1 124.42 111.4 136.86 –1.94 0.052
Hours under the inﬂuence of cannabis
per using daya
2.5 1.67 3.0 2.22 –2.24 0.027
Cannabis use disorder 8.0 (392/4888) 21.9 (47/215) 48.43 <0.001
Illicit drug use
Amphetamines/meth-amphetamines 3.1 (151/4880) 6.5 (14/214) 6.71 0.010
Ecstasy/MDMA 3.4 (167/4882) 8.4 (18/214) 13.20 <0.001
Hallucinogens 3.7 (179/4881) 9.3 (20/214) 16.13 <0.001
Heroin 0.4 (18/4882) 0.9 (2/214) 0.54 0.461
Cocaine/crack/freebase 2.9 (141/4882) 9.3 (20/214) 25.87 <0.001
Non-medical use of prescription drugs
ADHD medication (methylphenidate,
amphetamine sulphate)
1.7 (83/4.878) 5.6 (12/213) 15.15 <0.001
Sedatives (tranquillizers, hypnotics) 4.1 (201/4878) 12.2 (26/213) 29.45 <0.001
ASRS= adult ADHD Self-Report Scale; MDMA= 3,4-methylenedioxy-methamphetamine. aMenwho did not use this substance were excluded from this anal-
ysis, resulting in samples of n= 4653 for alcohol, n= 2186 for tobacco and n= 1537 for cannabis. bDue to variables’ positive skewness, values were trans-
formed into square roots and tested via t-test. The untransformed mean and standard deviation (SD) are presented for ease of interpretation of the results.
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those of 4888 men who were screened negative for ADHD
in a large sample of young Swiss men. Sizeable group differ-
ences in substance use and SUD were observed at baseline.
The ADHD+ group showed considerably higher prevalence
rates of alcohol, nicotine and cannabis use disorders and
patterns of heavier use than those in the ADHD– group.
In addition, the 12-month prevalence rates of illicit drug
use, except heroin, and of non-medical use of prescription
drugs were considerably higher in the ADHD+ group com-
pared to those of the ADHD– group. Many studies examin-
ing SUD prevalence rates and other substance use
outcomes in individuals with ADHD in early adulthood
suggested that ADHD was related to a greater likelihood
of use and abuse of a wide range of potentially addictive
substances [5,8]. This study conﬁrmed this association in
a large sample of Swiss men in early adulthood, enhancing
the validity of earlier studies.
An important ﬁnding was that when adjusting for CD
the changes in alcohol, tobacco and cannabis use
remained stable in both groups from baseline to follow-
up, indicating that the ADHD+ group continued to use
these substances more heavily compared to the ADHD–
group; the ADHD+ group neither increased (no escalation)
nor decreased their use relative to that of the ADHD–
group. Similarly, Breyer et al. [12] and Levy et al. [15] did
not observe any change in SUD prevalence rates over time.
However, they examined only substance dependence as an
outcome and did not consider use patterns.
The stable alcohol, tobacco and cannabis use patterns
in early adulthood in the present study may be related to
the age of participants. Commonly, age of onset for alcohol,
tobacco and cannabis use starts at an earlier age. For ex-
ample, Lambert et al. [14] reported the onset of alcohol
use at 13.8 years, of tobacco at 12.3 years and of cannabis
at 14.9 years. In individuals with childhood ADHD, Sibley
et al. [19] reported higher risk of alcohol, tobacco and can-
nabis use escalation by the age of 18years once abuse had
been initiated. The mean age of our sample was 20years;
therefore, the sample of the present study is ‘too old’ to
show an increase in already initiated substance use such
as alcohol, tobacco and the most prevalent drug, cannabis.
However, the ADHD+ group continued to use alcohol, to-
bacco and cannabis more heavily and frequently relative
to the ADHD– group.
Men in the ADHD+ group who did not already use the
corresponding substance at baseline were more likely to
initiate use of cannabis and some illicit drugs (e.g.
amphetamine/methamphetamine, hallucinogens and co-
caine) and to engage in non-medical use of prescription
drugs (i.e. ADHD medication and sedatives) between
baseline and follow-up compared to the ADHD– group.
This was not observed for alcohol, tobacco and
ecstasy/MDMA. Owing to our large sample size, we were
able to report that youngmenwith ADHDweremore likely
to initiate the use of certain drugs than those without
ADHD. Similarly, Levy et al. [15] observed a greater likeli-
hood of new-onset drug dependence in early adulthood in
individuals with childhood ADHD. However, their small
sample size and focus on the disorder rather than the
substance use prevented them from evaluating differences
between speciﬁc drug use. Higher rates of beginning
to use stimulant drugs, such as amphetamine/
methamphetamine and cocaine, and non-prescribed use
of ADHD medication in particular, support the hypothesis
that menwith ADHD seek the stimulating effects of certain
drugs (e.g. elevated concentration), possibly using them as
a form of self-medication [37]. However, in this study, the
ADHD+ group was also more likely to initiate the use of
sedatives, cannabis and even heroin, perhaps because they
sought a reduction in hyperactivity, which may remain at
20years of age and is more likely to decline in their mid-
to-late 20s [38,39]. Using substances of reasons for self-
medication could lower the threshold for initiation of the
use of other substances that may not have desired effects
on ADHD symptoms. This is more likely to occur in those
menwith ADHD, as they initiate substance usemore often.
Menwith ADHD could also bemore likely to experience co-
morbid psychiatric disorders such as depression or person-
ality disorders, elevating the risk of using addictive
substances [40].
These results did not change extensively when CD in
early adolescence was included as a mediator in the analy-
sis, revealing two important ﬁndings. First, CD elevated the
risk of initiation of use of all substances except alcohol, in-
dependently of ADHD, as reported in numerous other stud-
ies [11,13,16,18,23,24]. Therefore, CD alone carries a risk
of substance use and the interplay between ADHD and CD
exert additive effects, rendering young men even more
prone to substance use initiation [21]. Secondly, CD
Figure 2 Result of the random effect moderation analysis of attention
deﬁcit/hyperactivity disorder (ADHD) by conduct disorder (CD) on ini-
tiation of amphetamine/methamphetamine use. Result of the regression
analysis (y) includes the intercept (a = –2.04)
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exerted only a mediational effect on the association
between ADHD and initiation of ecstasy use but not on
those between ADHD and initiation of cannabis, stimu-
lants, hallucinogens or sedative use. These ﬁndings suggest
that ADHD carries a unique risk for substance use initia-
tion, which is independent of the presence of CD in early
adolescence, particularly for substances discussed within
the context of self-medication [21]. To date, only two
prospective studies have revealed a mediational effect of
CD. However, Brook et al. [22] examined SUD but did not
explore substance use initiation, and Sibley et al. [19]
examined alcohol, tobacco and cannabis use but did not
include other substances such as stimulants, including
non-prescription use of ADHD medication, the potential
use of which as a form of self-medication is high in men
with ADHD.
This study has important clinical implications, suggest-
ing that the use of an easily applicable screening instru-
ment for ADHD, the ASRS, could help to identify a group
of young men at particular risk of persistently high levels
of alcohol, tobacco and cannabis use and initiating use of
various drugs, including stimulants and sedatives. CD con-
tributes independently to elevated risk of initiation of use of
any substance except alcohol. This ﬁnding may be of spe-
ciﬁc interest within the context of (secondary) prevention
programmes, allowing a speciﬁc focus on high-risk men
in early adulthood.
Our results should be interpreted in the context of some
limitations. First, the ﬁndings are valid only for men and
may not be generalizable to women. However, in a meta-
analysis, Lee et al. [5] did not observe sex differences in in-
creased risk of developing SUD in individuals with ADHD.
Secondly, ADHD was assessed using the ASRS screening
instrument rather than structured diagnostic interviews;
therefore, the diagnosis of ADHD could not be conﬁrmed
via extensive clinical examination. Similarly, the
assessment of CD and substance use was based on
self-administered questionnaires. We cannot exclude the
possibility that some men may have under- or over-
reported their ADHD and CD symptoms or substance use.
However, the assessment instruments have been validated
[29,31,35,36,41]; in particular, the reliability and validity
of using self-report screening instruments to assess ADHD
[42], including ADHD in the context of SUD [43] in adults,
have been demonstrated in previous studies. Nevertheless,
we could not rule out the possibility that some men with
problematic substance use could have been more likely to
answer the ASRS items in the afﬁrmative, particularly as
van de Glind et al. [43] showed that the sensitivity of the
ASRS was high (r=0.88) but speciﬁcity was lower
(r=0.66). However, this issue was minimized, as only
men screened positive for ADHDwho did not use the corre-
sponding substance at baseline were included in initiation
analyses. Thirdly, self-medication was not assessed;
therefore, intention to use substances in this manner was
unknown and should be examined. Fourthly, surprisingly,
we could not ﬁnd signiﬁcant differences in education or
employment, but many studies have indicated that individ-
ualswith ADHD exhibit impairment in these domains [44].
In Switzerland, the education system supports pupils with
low performance as much as possible to ensure that they
are able to leave school with the best possible education.
In addition, men with ADHD may have held secure em-
ployment, as for several years the Swiss unemployment
rate has been approximately 3.2% [45]. Fifthly, the ADHD
prevalence rate was 4.2% in this Swiss sample, which is at
the lower end of the world-wide mean ADHD prevalence
rates, and 5.3% in individuals aged 18years or younger
[46], suggesting that the prevalence of ADHD could have
been under-represented. One reason could be that the
men who had been treated for ADHD via medication
and/or behavioural interventions may have lowered the
prevalence rate in the present sample. Sixthly, although
the total sample was large and the two groups were
matched closely on important socio-demographic variables
(e.g. same cantons, age, gender), the sample size of the
ADHD+ group was reduced considerably by a few analyses
of subgroups (e.g. initiation of alcohol use). Finally, while
the between-group differences were large at baseline some
effects were small for substance use initiation, possibly be-
cause the follow-up period was short at only 15months.
Future studies need to analyse the course of substance
use over a longer period.
CONCLUSIONS
Formen in their early 20s, ADHD is a risk factor for contin-
ued heavier but not escalating alcohol, tobacco and canna-
bis use when already consuming these substances. It is also
a risk factor for initiating the use of cannabis, stimulants
(i.e. amphetamines, cocaine and non-medical use ADHD
medication), hallucinogens and sedatives (i.e. non-medical
use of tranquillizers, hypnotics and heroin) when not
consuming these substances. CD contributes indepen-
dently to the risk of initiating the use of any substance,
except for alcohol, and it did not mediate the association
between ADHD and substance use. Young men with
ADHD appeared to be prone to using speciﬁc drugs, possi-
bly as a means of self-medication. A follow-up period of
longer than 15months would determine whether or not
this initiation pattern could be conﬁrmed. From a public
health perspective, the identiﬁcation of ADHD in early
adulthoodmay be relevant for early interventions designed
to lower the risk of drug use.
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